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A middle-aged Gauteng biologist, now
leading a full and normal life after
antiretroviral (ARV) drugs rescued him
from full-blown AIDS and a certain
death, is using his broad experience to
counsel doctors on the pitfalls of
treating people who are HIV-positive.
Peter Adams speaks passionately
about his medical nightmare and
confronting his own mortality after
being diagnosed HIV-positive in 1995
and beginning a  roller coaster ride
during which his CD4 cell count dipped
to as low as 69 (viral load 446 000).
He virtually loaned himself to science
as an ARV drugs guinea-pig, in the
process saving his own life and helping
doctors discover a great deal about
resistance testing.
Today he religiously takes his 10 pills
a day, his cell count is 853 and still
rising, and his viral load is
undetectable. 
His doctors confidently predict a 1 000
CD4 count within eighteen months as
his immune system continues to recover
on the custom-built drug regimen they
have settled on. His prognosis has been
revised from seven years (when he first
started on ARVs) to 20 years.
Adams recites a litany of harrowing
experiences as largely ignorant doctors
battled to come to terms with HIV-
positive people when the epidemic first
erupted in this country.
His lessons remain highly relevant,
especially to doctors in the public sector
where the provision of ARV drugs by
the state is imminent and to many
private practitioners only now coming
to terms with appropriate holistic
treatment for HIV-positive patients.
Adams helped establish Treatment
Helpline Direct, ran a drug adherence
programme for a major drug company,
has written 60 patient information
sheets (translated into several
languages) and is a regular lecturer at 
the Foundation for Professional
Development.
His advice does not always go down
well with doctors, for reasons varying
from professional pride to occasional
downright arrogance. Especially when
he tells them that they should be
dealing with all chronic conditions 'by
going back to the principles of
treatment 60 years ago — when you
were the family friend who brought
people into the world and wrote their
death certificates'.
'I tell them it's a journey you go on
together and that if they don't strike up
a relationship from day one, especially
with this disease, they ultimately risk
losing the patient.’ He believes the
pandemic will ensure that the practices
that suffer the most will belong to those
doctors who don't have the time or the
patience for people living with HIV.
Like the doctors he teaches, Adams
has been on a steep learning curve.
Unlike most of them he has been on
the sharpest end of the virus and borne
the stigma of those infected by it.
As many of his close friends died
around him between 1981 and 1995, he
remembers being tested for HIV
without his permission, being sent to a
liver specialist when his liver began
swelling and re-admitting himself to
hospital with severe breathing
difficulties.
'I lived in total oblivion and denial for
many of those years. I once entered the
emergency room and threw up at one
senior doctor's feet.’ He said in a loud
voice that everyone could hear, ‘this is
either cancer or AIDS’.
A deathly hush descended on the
busy unit and Adams was rushed off for
chest X-rays before being admitted to a
private ward where he was told that he
had pneumocystis and oral thrush.
'I noticed that they all stood at the foot
of the bed, wore rubber gloves and that
the other patient who was in the ward
with me was sent out.’
His counselling consisted of being
bluntly told he had full-blown AIDS
and that he'd have to change his
lifestyle.
'They said that from now on I'd have
to wash my apples and my lettuces —
they just simply didn't know how to
behave,' he said.
He was discharged after six days,
immediately went 'into the shakes and
hot and cold sweats’, and promptly re-
admitted himself.
He was finally wheeled out in a wheel
chair, having lost 13 kg and 'looking like
something out of a concentration camp'.
His own doctor was at a loss and
referred him to Dr Dennis Sifris, who
after initially giving him three months
to live, was to prove pivotal in Adams'
survival.
‘When he advised me to sort out my
affairs, say my goodbyes and take a
holiday and enjoy myself, I angrily gave
him the two fingers and told him I'd be
back.’
After a further two-week course of
Bactrim, Adams returned to Sifris and
begged him for some of the then limited
available drugs.
He was initially given AZT and
improved — before suddenly declining
again.
Sifris had in the meantime heard of a
clinical ARV trial (1996) but had one
problem — Adams' CD4 count was
above 300, too high to be considered a
candidate.
He believes the pandemic will
ensure that the practices that
suffer the most will belong to
those doctors who don't have
the time or the patience for
people living with HIV.
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The doctor/patient duo took a
decision — Adams came off treatment
so he could qualify.
'When I dropped below 250 I was the
happiest man in the world. Not only
was I on the trial, but the drugs were
free.’
The double-blind trial used AZT, 3TC
and nevirapine but because Adams was
already AZT-experienced, d4T was
used.
With the importance of adherence not
yet fully established, Adams first
improved rapidly, then failed.
'I was pill-adherent but not time-
adherent and there was no extensive
counselling then.’
A fourth drug, indinavir, was added
to his failing regimen and he promptly
ended up in hospital with kidney
stones.
'I once again went through that
embarrassment and indignity of having
to tell the hospital I was HIV-positive
and in a clinical trial on ARVs they'd
never heard of.’
When Adams ran out of treatment
options in South Africa, he travelled to
Europe in a last-ditch attempt to save
his life.
'It was nerve-wracking. All I was
concerned about was keeping it from
my (British) Mom and wondering how
she would cope if she found out,' he
said.
Adams and Sifris sourced a successful
treatment, but not after a gruelling and
expensive session of more tests
including one for resistance.
Adams had resistance to AZT, 3TC,
indinavir and initial cross-resistance to
the protease inhibitors, ritonavir and
saquinavir — but none to nevirapine.
'Every time you fail you have to
come to terms with your mortality all
over again and then pick yourself up.
Each time you fail it gets worse and
the sense of hopelessness looms. You
think, here we go again, are these drugs
really going to work?'
Adams said this is why it is so vital to
counsel patients from the outset of
treatment. 'Your first-line treatment is
not only your best chance of
suppressing the virus but it's the most
efficient from a psychological point of
view as well.’ In the USA5% of all new
HIV infections are drug-resistant strains
while in Europe 11% of all new HIV
infections are from a broad drug-
resistant virus.
Adams is now in his sixth year of
continuous undetectable viral load.
Research (Fiona Lamp et al.) has
shown that if the virus remains
undetectable in patients for three and a
half years and adherence is excellent,
chances of viral rebound are negligible.
Adams says every HIV-positive
person has the potential to achieve what
he has.
He handles patient-advice-resistant
doctors with aplomb.
'Alot of them initially didn't like the
idea of a patient presenting,' he says.
One drum he beats loudly and
consistently is that of doctors 'coming
off their pedestals'.
'If you want your patient to adhere
and co-operate you've got to get out
from behind your desk and stand next
to them — otherwise they'll just tell you
what you want to hear.’
Becoming a patient’s friend does not
imply any loss of status, he adds.
It might save their life.
Don't take Adams' word for it.
Ask Sifris.
Chris Bateman
'Your first-line treatment is
not only your best chance of
suppressing the virus but it's
the most efficient from a
psychological point of view as
well'.
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